US Patent Issued to IMMUNESURE on March 24 for "RNA-based adjuvant to enhance the immune response to vaccines and therapeutics" (New York, Colorado Inventors)

ALEXANDRIA, Va., March 24 -- United States Patent no. 12,582,711, issued on March 24, was assigned to IMMUNESURE LLC (Lebanon, Ore.).

"RNA-based adjuvant to enhance the immune response to vaccines and therapeutics" was invented by Patrick Iversen (Grand Junction, Colo.), Nickolas Kipshidze (New York) and Nodar Kipshidze (New York).

According to the abstract* released by the U.S. Patent & Trademark Office: "Described herein are antisense inhibitor adjuvant compositions comprising modified nucleotide sequences complementary to a Homo sapiens interleukin 10 (IL-10) or interleukin 10 receptor alpha (IL-10RA) genes and methods for use thereof."

The patent was filed on Aug. 18, 2022, under Application No. 17/820,623.

*For further information,...